Elily和Cipla发射的Yurpeak(一种通用的tirzepatide)在印度扩大糖尿病和减重药物的获取范围。 Eli Lilly and Cipla launch Yurpeak, a generic tirzepatide, in India to expand diabetes and weight-loss drug access.

Elily和Cipla合作在印度推出名为Yurpeak的tirzepatide, 扩大获得糖尿病和体重调控药物的机会。 Eli Lilly and Cipla have partnered to launch tirzepatide, branded as Yurpeak, in India, expanding access to the diabetes and weight-management drug. Cipla将处理销售和分销,Lilly则以其Mounjaro品牌的同样价格制造和供应该药物。 Cipla will handle marketing and distribution while Lilly manufactures and supplies the drug at the same price as its Mounjaro brand. Yurpeak作为每周一次的预先装满六剂的笔提供,目的是接触城市地区以外的病人。 Yurpeak, available as a once-weekly pre-filled pen in six doses, aims to reach patients beyond urban areas. 在Lilly于2025年3月发射Mounjaro及6月批准KwikPen装置后, The move follows Lilly’s March 2025 launch of Mounjaro and its June approval for the KwikPen device, which helped double sales.